Aims Glutamate decarboxylase (GAD) antibodies are the most widely used predictive marker for Type 1 diabetes, but many individuals currently found to be GAD antibody-positive are unlikely to develop diabetes. We have shown previously that radioimmunoassays using N-terminally truncated 35 S-GAD 65 (96-585) offer better disease specificity with similar sensitivity to full-length 35 S-GAD 65 (1-585). To determine whether assay performance could be improved further, we evaluated a more radically truncated 35 S-GAD 65 (143-585) radiolabel.
Introduction
Approximately 80% of children diagnosed with Type 1 diabetes have glutamate decarboxylase antibodies [1] . This marker is used widely, both clinically and in research, to identify individuals at increased risk of Type 1 diabetes, assisting in diabetes diagnosis and as an inclusion criterion for therapeutic intervention trials [2] . although requiring more serum per test than radioimmunoassays (50 ll vs. 4 ll, respectively), consistently showed higher specificity in international workshops [9] . This improved specificity may be explained in part by reduced access of autoantibodies to the N-terminus of GAD 65 in the ELISA configuration. The primary antigenic region of Type 1 diabetes-associated GAD antibodies is found in the middle and C-terminus of GAD 65 ; antibodies recognizing only the N-terminal region were not associated with progression to multiple islet autoimmunity or diabetes [10, 11] . We therefore developed an N-terminally truncated GAD 65 radiolabel, 35 S-GAD 65 (96-585), for use as tracer. Removing the first 95 amino acids, comprising the first three exons of GAD 65 [12, 13] increased the specificity of GAD antibody radioimmunoassays without loss of sensitivity, improving their workshop performance [11] . We also demonstrated that autoantibodies measured with this construct, in firstdegree relatives (FDRs) of people with Type 1 diabetes, were more closely associated with diabetes risk [14] . Fewer than half of FDRs found positive for GAD 65 (96-585) antibodies by radioimmunoassay, however, were likely to develop diabetes within 25 years. To discover whether further N-terminal truncation could improve the specificity of GAD antibody measurement by radioimmunoassay, we evaluated several GAD 65 constructs in which regions up to and including exon 6 were deleted (Fig. 1a,b) . We also investigated how GAD antibody levels measured by radioimmunoassay with truncated GAD 65 labels or by ELISA compared, and examined how positivity by each method contributed to the overall risk of developing diabetes.
Methods

Population
Bart's-Oxford family study Sera were available from the Bart's-Oxford (BOX) family study. This population-based study was established in 1985 [15] and has recruited more than 3000 children with Type 1 diabetes diagnosed before the age of 21 years in the Oxford region of the UK, 76% of whom are still followed up. Today, over 6000 FDRs of the probands have been recruited and followed prospectively for disease development by annual questionnaire. Samples from 4470 diabetes-free relatives were tested for autoantibodies to insulin, full-length GAD 65 and islet antigen-2, using established local assays [16] . Those found to be antibody-positive were also tested for autoantibodies to zinc transporter 8 (ZnT8) [17] . (Fig. 1c) .
Cohorts for evaluating the performance of GAD(143-585)
antibody Sera with sufficient volume from 157 people (94 male; median age 11.7 years, age range 1.3-20.9 years) with recent-onset Type 1 diabetes (median duration 1 day, range À7 to 90 days) were selected at random from 613 participants [14] to determine the disease sensitivity of GAD antibody measurement using the N-terminally truncated 35 S-GAD 65 constructs (Table 1 , Fig. 2a ).
To evaluate discrimination of risk of diabetes progression, sera were available from 282 (138 male; median age 31.4 years, range 1.3-57.4 years) of 283 FDRs previously found to be GAD antibody-positive with the local radioimmunoassay (Table 1, Fig. 2b ).
Assay specificity was further evaluated by testing the first available sample from 463 FDRs (229 male; median age 33.3 years, age range 1.4-57.3 years) who previously tested GAD 65 (1-585) antibody negative with the local radioimmunoassay. Samples were selected at random from 4187 GAD antibody-negative individuals but were enriched with 33 of 179 individuals who developed diabetes during followup (Table 1 , Fig. 2b ) [14] .
What's new?
• The N-terminus of glutamate decarboxylase (GAD 65 ) contributes little to epitopes recognized by Type 1 diabetes associated GAD antibodies.
• Radioimmunoassays using N-terminally truncated 35 S-GAD 65 (96-585) improve the specificity of GAD antibody measurement.
• We show that using a more radically truncated 35 S-GAD 65 (143-585) radiolabel to measure GAD antibodies does not impact assay sensitivity and improves diabetes specificity compared with full-length 35 S-GAD 65 (1-585).
• Relatives of people with Type 1 diabetes who were GAD antibody-positive using truncated radiolabels had increased risk of progression to diabetes within 15 years compared with those positive for GAD(1-585) antibody alone, and were at similar risk to those found positive using a high-performing commercial GAD antibody enzyme-linked immunosorbent assay. [14, 16] .
Autoantibody assays
Radioimmunoassay
Sera (2 ll, in duplicate) screened using the local GAD antibody assay [16] were remeasured using the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) harmonized GAD antibody radioimmunoassay protocol [6] . was read. Results were converted to NIBSC 97/550 units using the calibrators provided.
Antibody thresholds
Thresholds for the harmonized GAD antibody radioimmunoassays that used the three GAD 65 constructs investigated in detail were set at the 97.5th percentile of 221 healthy schoolchildren (Fig. 2a ) [18] , equal to 13.5, 12.8 and 11.8 DK units/ml for Because of limited serum availability, the threshold for the GAD antibody ELISA was set at the 97.5th percentile of 180 of the 221 healthy schoolchildren, equal to 6.0 NIBSC 97/ 550 units (Fig. S1 ). The equivalent thresholds were 12.9, 14.0 and 11. 
Statistical analysis
Wilcoxon matched-pairs signed-ranked test was used to compare signal-to-noise ratios (SNRs) and McNemar's test with Yate's correction for comparing antibody status between constructs and assay formats. The Kaplan-Meier test was used for survival analysis and the Mantel-Cox logrank test for comparing survival between groups. For all analyses, a two-tailed P-value of < 0.05 was considered significant. The partial area (90th percentile) under the curve (pAUC) of the receiver operating characteristic (ROC) with 95% confidence intervals (CI) was calculated assuming a nonparametric distribution of results using R software, version 3.2.2. Other statistical analyses were performed using GraphPad Prism version 6.
Results
Initial construct screening N-terminally truncated 35 S-GAD 65 constructs were screened in the initial evaluation ( Fig. 1) to discover which were likely to offer the best discrimination between diabetes and nonprogression. A SNR (sample cpm Ä negative standard cpm) was calculated using a negative standard included in all assays. The S3a) . Sensitivity at 95% specificity (AS95) was 84% for all three constructs. Sensitivity was also similar in the 109 relatives who progressed to diabetes during follow-up and/or had autoantibodies to additional islet antigens (Table S2) 
258
Tested for GAD antibodies (GADA) using ELISA FIGURE 2 Selection scheme of samples tested for GAD antibodies using radioimmunoassay or ELISA, showing radioimmunoassay results for (a) healthy schoolchildren and people with recent-onset Type 1 diabetes or (b) BOX relatives. Samples were re-assayed with the NIDDK harmonized radioimmunoassay protocol using S-GAD 65 (143-585), and a proportion assayed using ELISA. Similar numbers of patients were found to be positive for GAD antibodies using all three radiolabelled constructs. Fewer relatives who were found previously to be GAD antibody-positive using a local assay were positive on re-assay for GAD(96-585) or GAD(143-585) antibodies compared with GAD(1-585) antibodies (P < 0.0001, for all).
high-risk relatives were positive for all three specificities.
Fewer GAD(1-585) antibody-positive relatives who had no additional islet autoantibodies and had not progressed to diabetes tested positive using truncated 35 
S-GAD 65 constructs
Of the 173 low-risk relatives, 156 (90%) were positive for GAD(1-585) antibodies compared with 108 (62%) for GAD (96-585) antibodies (P < 0.0001) and 98 (57%) for GAD (143-585) antibodies (P < 0.0001). The proportion of these low-risk relatives found positive for GAD(143-585) antibodies was reduced compared with those positive for GAD (96-585) antibodies (P = 0.02) ( Table S3) . In 258 relatives who tested GAD antibody-positive using the harmonized radioimmunoassay with 35 S-GAD 65 (1-585), the 15-year risk of diabetes was 26% (95% CI 20-32%). Within this group, positivity for GAD(96-585) and GAD (143-585) antibodies showed a similar ability to further stratify diabetes risk (P < 0.0001, for both). Nevertheless, positivity for GAD(143-585) antibodies did not improve discrimination of risk compared with GAD(96-585) antibodies. Individuals positive for GAD(96-585) antibodies had a 33% (95% CI 26-41%) risk of developing diabetes within 15 years, whereas individuals positive for GAD(143-585) antibodies had a 34% (95% CI 27-42%) risk (Fig. 3a) .
Sensitivities of the ELISA and radioimmunoassays in people with Type 1 diabetes and high-risk individuals were similar
The prevalence of GAD antibodies in the 81 people with Type 1 diabetes measured by ELISA (86%) was similar to that in the same individuals measured by radioimmunoassay (80% for all three constructs, P > 0.05 for all comparisons) (Table S4 and Fig S1) . ROC analysis of these 81 people with Type 1 diabetes and 180 healthy schoolchildren, found the pAUC for GAD antibodies measured by ELISA was 0.084 (95% CI 0.076-0.091), compared with 0.077 for GAD(1-585) antibodies (95% CI 0.069-0.085), 0.076 for GAD(96-585) antibodies (95% CI 0.066-0.085) and 0.077 for GAD(143-585) antibodies (95% CI 0.069-0.084) when measured by radioimmunoassay (P > 0.05 for all comparisons) (Fig. S3b) . AS95 was 84%, 86%, 85% and 89% for GAD(1-585), GAD(96-585) and GAD(143-585) antibodies and the ELISA, respectively.
Of 85 relatives who progressed to diabetes and/or had autoantibodies to additional islet antigens, 74 (87%) were found GAD antibody-positive by ELISA compared with 78 (92%, P > 0.05), 71 (84%, P > 0.05) and 76 (89%, P > 0.05) found positive for GAD(1-585), GAD(96-585) and GAD(143-585) antibodies by radioimmunoassay, respectively (Table S4) .
Fewer GAD(1-585) antibody-positive relatives who had no additional islet autoantibodies and had not progressed to diabetes tested positive using the ELISA Of the 173 low-risk GAD antibody-positive relatives, 77 (45%) retested positive by ELISA compared with 156 (90%, P < 0.0001) using 35 S-GAD 65 (1-585), 105 (61%, P < 0.0001) using 35 S-GAD 65 (96-585) and 98 (57%, P = 0.0001) using 35 S-GAD 65 (143-585) (Table S5 ). (Fig. 3b) .
Relatives who previously screened GAD antibody negative
Of 463 relatives who previously tested negative for GAD antibodies using the local radioimmunoassay, 12 (3%) retested positive for GAD(1-585) antibodies, seven (2%) for GAD(96-585) antibodies and 13 (3%) for GAD(143-585) antibodies (P > 0.05 for all comparisons). Three samples were positive with all three truncated constructs (Fig. 2b) . Within this subset, 33 relatives had progressed to diabetes. Of these, none were positive for GAD(1-585) antibodies, one (3%) was positive for GAD(96-585) antibodies and two (6%) for GAD(143-585) antibodies (Tables S2 and S3) . Similar results were seen for the 389 GAD antibodynegative relatives who did not progress to diabetes during follow-up, as 11 (3%) were positive using the ELISA compared with eight (2%, P > 0.05) using 35 S-GAD 65 (1-585), three (1%, P = 0.04) with 35 S-GAD 65 (96-585) and nine (2%, P > 0.05) with 35 S-GAD 65 (143-585) (Table S5) .
Of the relatives who progressed, 29 were tested for GAD antibodies using ELISA; one (3%) of these was positive with ELISA, whereas a different sample (3%) was positive using 35 S-GAD 65 (143-585) (Table S4) .
Discussion
A similar proportion of people with Type 1 diabetes and relatives who progressed to diabetes were found positive for GAD antibodies with radioimmunoassays using 35 S-GAD 65 (96-585) and 35 S-GAD 65 (143-585) or full-length 35 S-GAD 65 , indicating that sensitivity was maintained using the N-terminally truncated GAD 65 constructs. Furthermore, relatives positive for GAD antibodies using these truncated labels were at increased risk of progression to diabetes within 15 years compared with those who retested positive for GAD (1-585) antibodies using the harmonized assay, and at similar risk to those found GAD antibody-positive using the commercial ELISA.
This study benefits from the inclusion of many participants selected from a well-characterized, population-based family study with common assay thresholds set using a schoolchild cohort from the same geographical area. Although the relatives analysed were not followed from birth, and may not be perfectly representative of the general population, they nonetheless provide a unique opportunity to study the relationship between the autoantibody response to GAD 65 and diabetes development over a prolonged followup, extending up to 30 years. In addition, all samples from people with Type 1 diabetes were collected within 3 months of diagnosis, minimizing the likelihood of negative seroconversion. Furthermore, antibodies to the 35 S-GAD 65 constructs have been measured using standardized and validated radioimmunoassays, whose performance was assessed in international workshops [6, 9, 11] . Limitations of our study were that all samples were pre-screened using a local fulllength GAD autoantibody radioimmunoassay and we were unable to test all samples by ELISA, because of inadequate serum volumes. A large cohort of GAD antibody-negative relatives was included to address any resulting selection bias and help evaluate the performance of the different assays when used for primary screening. Overall, these attributes allowed a detailed evaluation of disease specificity and sensitivity. Studies using engineered GAD 65 proteins or monoclonal antibodies demonstrated that GAD antibodies associated with Type 1 diabetes primarily target epitopes found in the middle and C-terminal domains of GAD 65 [19] [20] [21] [22] [23] [24] [25] . Using GAD67/65 chimeras, the BABYDIAB study identified the primary GAD antibody epitope within GAD 65 residues 96-444, with epitope spreading to the N-terminal region being common [26] . Another group using competition radioimmunoassays with recombinant Fabs of four GAD 65 -specific monoclonal antibodies, found that epitope spreading from the C-terminus (amino acids 483-585) and middle region (amino acids 195-365) to the N-terminus (amino acids 96-173) was associated with progression, while epitope reactivity was stable in low-risk individuals [27] . This approach was also used to characterize GAD antibody epitopes in a small selection of people with Type 1 diabetes or latent autoimmune diabetes of adults, FDRs and healthy individuals. Competition with a Fab recognizing amino acids 96-173 (DP-D) reduced median binding by 80%. In people with Type 1 diabetes, 3% were fully inhibited by DP-D and 62% partially, implicating these amino acids as contributors to a disease-specific epitope. Although this inhibition may be related to amino acids 143-173, the discrepancy with our findings could be explained by effects of Fab binding on other regions of the molecule. Of note, GAD antibody-positive samples inhibited by a Fab recognizing amino acids 308-365 also showed competition by DP-D (P = 0.006) [24] .
We investigated a range of truncated constructs including GAD 65 (115-585), GAD 65 (143-585), GAD 65 (160-585), GAD 65 (188-585) and GAD 65 (242-585). Removal of amino acids up to position 188 had only a small impact on binding in people with Type 1 diabetes compared with 35 S-GAD 65 (96-585), whereas truncation at position 242, comprising the first 6 exons, severely reduced binding in sera from people with Type 1 diabetes. These findings suggest that truncations up to position 188 are unlikely to disrupt folding of the major GAD antibody epitopes but confirm that residues 188-242 are probably critically important to the integrity of diabetesrelevant epitopes [24, 27] . Although antibody binding was reduced in low-risk samples using 35 S-GAD 65 (160-585) and 35 S-GAD 65 (188-585), critically, the poor SNRs seen with these constructs resulted from increased background binding. Consequently, 35 S-GAD 65 (143-585) was selected for detailed evaluation. Overall, a small improvement in disease specificity, without a loss of sensitivity was seen with this FIGURE 3 (a) Kaplan-Meier survival curve for 258 first-degree relatives found positive for GAD S-GAD 65 (143-585) and the ELISA method identified relatives at increased risk of diabetes progression (P < 0.0001, respectively). Individuals positive for GAD(96-585) antibodies had a 28% (95% CI 21-36%) risk of developing diabetes within 15 years, whereas those positive for GAD(143-585) antibodies had a 29% (95% CI 22-38%) risk and individuals found positive using ELISA had a 31% (95% CI 24-41%) risk. Few relatives who were positive for GAD(1-585) antibodies but negative for GAD(96-585) and GAD(143-585) antibodies or by ELISA developed diabetes within 30 years of follow-up.
construct when compared with 35 S-GAD 65 (96-585), indicating that the first 142 amino acids do not make an important contribution to Type 1 diabetes-associated GAD antibody epitopes. Assays using more radically truncated GAD 65 antigens could, therefore, offer alternatives to GAD 65 (96-585) for GAD antibody measurement.
The commercial GAD antibody ELISA performed well, but did not offer significant improvements in discriminating risk of developing diabetes within 15 years, compared with radioimmunoassays using the truncated 35 S-GAD 65 (96-585) or 35 S-GAD 65 (143-585) constructs. Improved specificity may be expected when re-assaying samples using a different method, as non-specific binding is less likely to be reproduced in a different assay format. However, we found little evidence that the ELISA would identify additional progressors who screened negative by radioimmunoassay. Furthermore, the ELISA requires 50 ll serum per test, compared with only 4 ll for the radioimmunoassay. This is an important consideration, as GAD antibody seroconversion often occurs in early infancy, and therefore early childhood is considered the optimum age for population screening for Type 1 diabetes. Capillary blood samples, which can facilitate population screening and recruitment to trials, typically yield < 100 ll serum [28, 29] . Lowvolume radioimmunoassays with a proven track record therefore provide a useful tool for Type 1 diabetes prediction. The flexibility of this method enables detailed epitope characterization using truncated GAD 65 antigens and chimeras, which may help to further delineate the autoimmune response. Radioimmunoassay can also evaluate other autoantibody features, such as affinity, which may further discriminate risk in GAD antibody-positive individuals [10, 30] . We have shown that individuals who are positive for GAD antibodies measured using truncated 35 S-labelled GAD 65 constructs have a higher risk of developing diabetes compared with those positive for full-length GAD antibodies. Thus, positivity for GAD(96-585) or GAD(143-585) antibodies may be a useful inclusion criterion for therapeutic intervention trials which target high-risk individuals.
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